Author:
Ruperto Mar,Montero-Bravo Ana,Partearroyo Teresa,Puga Ana M.,Varela-Moreiras Gregorio,Samaniego-Vaesken Maria de Lourdes
Abstract
Foods for special medical purposes (FSMPs) are commercially available formulations used as a source of nutrition when administered orally or by tube feeding. This study examines, for the first time, the nutritional composition of enteral formulae (EFs) according to European nutritional guidelines. We developed a descriptive study on 118 EFs from 2020 to 2021. Formulae were classified as standard (SFs) and disease-specific (DSF). According to the protein-energy content, SFs were classified into G1, normoprotein-normocaloric; G2, normoprotein-hypercaloric; G3, hyperproteic-normocaloric; and G4, hyperproteic-hypercaloric. Disease-related formulae for metabolic stress, renal, cancer, pulmonary, diabetes, malabsorption, and surgery were studied. Macronutrient distribution, fatty acid profile (monounsaturated [MUFA], polyunsaturated [PUFA], saturated [SFA]), derived fat quality indexes, and immuno-modulatory nutrients (omega-3, eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], arginine and nucleotides) per 1,500 kcal infused were calculated. In total, 53% were SFs, mainly normoproteic (G1, G2) with higher carbohydrate contents in normocaloric vs. hypercaloric SFs. The most balanced fatty acid profiles (MUFA: 17.7%; PUFA: 6.8%; SFA: 9.5%) belonged to G1. The PUFA/MUFA ratio: ≥0.5 was in 85.7% with a higher proportion of EPA+DHA (46%) vs. omega-3 (15.8%) in SFs. In DSFs (46.9%), higher carbohydrate content (>50%) was in malabsorption and surgery, whereas high-fat content (>50%) was in pulmonary and renal formulae. DSFs had higher SFA vs. MUFA content, except for diabetes. EPA and DHA were added in 45.5% (cancer, malabsorption, and surgery). Only 12.7% of DSFs had arginine and nucleotides. A higher proportion of SFs was found, in line with current European guidelines. Results highlighted a wide intra-group variability of nutrients among the formula selected. These findings are useful to evaluate the nutritional composition of EFs from a preventive and/or therapeutic perspective in clinical settings.
Subject
Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Food Science
Reference45 articles.
1. The European fight against malnutrition;Ljungqvist;Clin Nutr.,2010
2. Commission E. Comission Decision of 17.7.2018 Setting Up a Commission Expert Group “Steering Group on Health Promotion, Disease Prevention and Management of Non-Communicable Diseases” and Repealing the Decision Setting Up a Commission Expert Group on Rare Diseases and the Decision Establishing a Commission Expert Group on Cancer Control
3. Europe Clinical Nutrition Market Research Report- By Product Type BTA By Ingredients Type and By Country (UK France Spain Germany Italy Russia Sweden Denmark Switzerland Netherlands Turkey Czech Czech Republic and Rest of Europe) - Size Share. Growth, Trends, and Forecast (2021 to 2026)
4. ESPEN guidelines on definitions and terminology of clinical nutrition;Cederholm;Clin Nutr.,2017
5. ESPEN guideline on home enteral nutrition;Bischoff;Clin Nutr.,2020